<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136342</url>
  </required_header>
  <id_info>
    <org_study_id>LYS-I-01</org_study_id>
    <nct_id>NCT02136342</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer</brief_title>
  <official_title>Phase 1 Trial Evaluating Tolerability and Pharmacokinetics of Chlorogenic Acid for Injection in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore if chlorogenic acid is safe in patients with cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study site change
  </why_stopped>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>within the first 60 days after the first dose of chlorogenic acid</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>dose-limiting toxicity</measure>
    <time_frame>within the first 30 days after the first dose of chlorogenic acid</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>within the first 30 days after the first dose of chlorogenic acid</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of chlorogenic acid</measure>
    <time_frame>within the first 30 days after the first dose of chlorogenic acid</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in cancer-related symptoms and quality of life</measure>
    <time_frame>within 1 year after the first dose of chlorogenic acid</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in number of red blood cell and level of hemoglobin</measure>
    <time_frame>within 1 year after the first dose of chlorogenic acid</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in the diameters of lymph node metastasis</measure>
    <time_frame>within 1 year after the first dose of chlorogenic acid</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in levels of tumor markers</measure>
    <time_frame>within 1 year after the first dose of chlorogenic acid</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>chlorogenic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorogenic acid</intervention_name>
    <arm_group_label>chlorogenic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  advanced cancer with no effective treatment

          -  Karnofsky performance status no less than 70

          -  adequated organ function

          -  informed consent

        Exclusion Criteria:

          -  allergic to chlorogenic acid

          -  persistent toxicities from previous treatment (no less than grade 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <last_update_submitted>October 19, 2014</last_update_submitted>
  <last_update_submitted_qc>October 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>no available effective treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

